Sri Lanka vs Yemen: HIV/AIDS deaths averted by antiretroviral therapy
Sri Lanka
217.06 deaths
in 2024
Yemen
267.91 deaths
in 2024
Sri Lanka rank
109th
Yemen rank
106th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Sri Lanka
- Yemen
How they compare
Yemen currently reports 267.91 deaths against 217.06 deaths in Sri Lanka, a difference of 50.85 deaths.
That makes Yemen's figure about 1.2 times Sri Lanka's.
The two have swapped places 2 times across 35 shared years of data; in 1990 it was Yemen ahead.
Sri Lanka ranks 109th and Yemen ranks 106th of 157 countries.
Across the 4 decades both report, Sri Lanka averaged higher in 1 and Yemen in 2.
Head to head by decade
| Decade | Sri Lanka | Yemen | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0 deaths | 0 deaths | — |
| 2000s | 11.47 deaths | 10.16 deaths | 1.31 deaths | Sri Lanka |
| 2010s | 86.12 deaths | 127.01 deaths | 40.89 deaths | Yemen |
| 2020s | 187.06 deaths | 218.27 deaths | 31.21 deaths | Yemen |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Sri Lanka or Yemen?
- Yemen, at 267.91 deaths against 217.06 deaths in Sri Lanka as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Sri Lanka and Yemen?
- 50.85 deaths, with Yemen ahead.
- How many years of comparable data are there for Sri Lanka and Yemen?
- 35 years are reported by both, from 1990 to 2024.
- How do Sri Lanka and Yemen rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Sri Lanka ranks 109th and Yemen ranks 106th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.